The antiviral drug remdesivir has had little or no effect in treating hospitalized patients with Covid-19, according to a study that has not yet been peer-reviewed but was coordinated by the World Health Organization and released Thursday, casting doubt. one of the few promising treatments for coronavirus.
Considering it “the largest randomized control study in the world of Covid-19 therapies”, the six-month study of four drugs – remdesivir, hydroxychloroquine, lopinavir / ritonavir and interferon – turned out to be “unpromising”.
“The main outcomes of mortality, onset of ventilation and length of hospitalization were not clearly reduced by any study drug,” the study reads.
Over 11,000 adults in 30 countries and 405 hospitals were studied to arrive at these results.
Regimens involving the antimalarial drug hydroxychloroquine have already proved ineffective, but remdesivir appeared to be one of the few therapies to prove effective in combating the symptoms of Covid-19.
The WHO results come just a week after a study published in New England Journal of Medicine who found that remdesivir reduced recovery times for adults hospitalized with Covid-19.
President Trump, who contracted Covid-19 and spent time at Walter Reed hospital for symptoms, was given remdesivir as part of his treatment.
Remdesivir is the only specific drug with an emergency use authorization from the Food and Drug Administration. Approval of a Covid-19 vaccine isn’t expected until the end of the year and, even then, it will take months before there is a fairly widespread distribution. Several countries such as France are experiencing record numbers of daily cases in October. The United States continues to be the hardest hit. Despite having 4% of the world’s population, the country owns nearly 21% of all cases with nearly 8 million and 20% of global deaths with around 218,000.
Gilead’s gains in the stock market during the pandemic have completely dissipated. Its price has risen 29% since the beginning of the year before dropping 3% below its position in January.
Full coverage and real-time updates on the Coronavirus